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Abstract  
 
Cancer is the leading cause of death in Indonesia. Generally, cancer therapy use 
chemotherapy, radiation, surgery or combination of those. Various side effects caused by 
cancer therapy make the use of additional drugs. This leads to an increase in total cost 
incurred to cancer patients. The purpose of this study was to describe the treatment of 
cancer therapy’s side effects as well as the average cost of side effects treatment, and its 
percentage in the total cost of cancer patients in Rumah Sakit Margono Soekarjo. This 
research was a descriptive study with retrospective data by total sampling method obtained 
from patients’ medical and receipts records of five most common cancers (breast, 
nasopharynx, Non Hodgkins Lhympoma (NHL), ovarian, and cervix) during January-
December 2010. The average cost of patient’s side effects treatment was calculated by the 
average cost of side effects compared to the average total direct costs incurred to cancer 
patients. The samples was obtained from the population of 2261 patients who met the 
inclusion criteria, that are 73 patients consist of 62 female patients and 11 male patients. The 
most common side effects of cancer therapy were nausea and vomiting (59.80%), nausea-
vomiting, anemia, and pain (16.44%), and nausea-vomiting and anemia (15.07%). The most 
used therapy was vitamin B complex followed by histamine-2 inhibitor. The average cost of 
side effects for breast cancer was Rp 1,715,373 (8.73%), nasopharynx was Rp 1,149,049 (6.98 
%); NHL was Rp 360,778 (1.97 %); ovary was Rp 911,118 (3.61 %) and cervical was Rp 
1,416,027 (8.87 %). The results indicated that the hospital needs to pay more attention on 
nausea-vomiting effect of chemotherapy, and also cervical cancer side effects therapy as the 
most costly. 
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INTRODUCTION 
 
Cancer is a disease characterized with 
uncontrolled cells differentiation and 
proliferation. It causes cells continuing to grow, 
to spread abnormally, and to invade other 
normal cells, causing metabolic disorders and 
may lead to death if the cancer was not cured 
(Katzung, 2007). There are various therapies 
that can be done to treat cancer. Surgery, 
radiotherapy, chemotherapy, or combination of 
them, are widely used to treat cancer. 
Nevertheless, cancer therapy’s side effects are 
well known to cause clinical and economical 
burden (Anonymous, 2009; WHO, 2005). 
Cancer therapy side effects can reduce 
patients’ quality of life.  Moreover, there is also 
economic effect because of it. Additional drugs 
are required to treat chemotherapy side effects, 
thus there will be increase of total cost spent by 
either cancer patients or other payers, such as 
insurance (Balmer et al., 2005). The number of 
cancer patients in Rumah Sakit Prof. Dr. 
Margono Soekarjo (RSMS) in 2010 is about 
3369 patients. 
Cancer rate is followed by the incidence 
of side effects of therapy. There are many side 
effects that frequently occur, such as nausea, 
vomiting, and anemia. Nausea is defined as the 
feeling of wanting to vomit or craving 
symptoms experienced around the throat and 
stomach, indicating that the patient will soon 
vomit.  
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Vomiting is defined as the expulsion of gastric 
contents, which sometimes requires a strong 
boost
 
(Garret et al., 2003). Nausea and vomiting 
can be either acute, delayed, or anticipatory. 
The stimulation of central vomiting and 
chemoreceptor trigger zone by chemotherapy 
can induce nausea. Chemotherapy also causes 
enterochromaffin cell damage, thus serotonin 
release occurs to stimulate chemreceptor trigger 
zone to induce nausea. The example of 
chemotherapeutic agents that induce nausea and 
vomiting are alkylating agents (Dipiro et al., 
2005) 
Anemia is a myelosuppressive effect. 
Myelosuppressive is the decrease of bone 
marrow efficiency/capacity to produce blood 
cells. It can be caused by cancer therapy. 
Chemotherapeutic agents kill functional cells 
that are in charge if producing blood cells, such 
as erythrocyte, leukocyte, thrombocytes, and 
others. So the amounts of those cells in the 
body were decreased (Amy, 2009). Anemia is a 
symptom characterized by low hemoglobin 
level, which is usually less than 10 g/dl (WHO, 
2006). It can be caused by the depression of 
bone marrow or by nephrotoxicity of 
chemotherapeutic agent inducing the decrease 
of erythropoietin production. Cisplatin is one 
alkylating agent which has nephrotoxicity as 
the side effect (Rodgers, 2008). Other side 
effects of cancer therapy are mucositis, 
alopecia, cardiotoxicity, and suffering pain 
(NCI, 2012). 
The purpose of this study was to describe 
the treatment of side-effects from cancer 
therapy as well as the average cost of them, 
together with the percentage of cancer patients 
in Margono Soekarjo Hospital. The results of 
this study can be referred as an advice for 
hospital management to choice effective 
therapy for cancer side effects treatment. 
 
MATERIALS AND METHODS 
 
Study Design 
The study was a descriptive study with 
retrospective data by total sampling method 
obtained from patients’ medical and receipts 
records of five most common cancers [breast, 
nasopharynx, Non Hodgkins Lhympoma 
(NHL), ovarian, and cervical] in Rumah Sakit 
Prof. Dr. Margono Soekarjo (RSMS) during 
January-December 2010. The study was 
conducted on April-July 2012. 
 
Study Subjects 
The total of 2261 patients of top 5 
cancers patients were selected by inclusion 
criteria. The inclusion criteria were patients 
with diagnosis of cancer, either with or without 
comorbidities and having documentation of 
therapy’s side effect, patients with complete 
medical and receipts records, and patients who 
have completed 6 chemotherapy cycles. The 
inclusion criteria selected 73 patients from 
those 2261, and total sampling method was 
used to all the 73 patients to be the subjects of 
the study. Data were collected from medical 
and receipts office in Rumah Sakit Margono 
Soekarjo Purwokerto. 
 
Data Collection 
Data collection was done by using data 
collection sheet. Data collection sheet was used 
to record data from medical and receipts 
records. Medical data recorded were medical 
record number, gender, age, diagnose, therapy 
documentation, side effects documentation, 
laboratory data, and status of cancer. Receipts 
data recorded were the detailed therapy cost and 
total cost spent by cancer patients. 
 
Data Analysis 
Data from medical record were analyzed 
and described based on the types and the 
therapy of cancer therapy’s side effects. That 
data also described the pattern of cancer and 
cancer treatment’s side effect therapy. Data 
from receipts records were analyzed and 
components of the cost of therapy side effects 
incurred to the patients during treatment were 
compared to the overall total direct cost. The 
average percentage of the cost of the side 
effects treatments was determined by the 
average cost of side effects treatments 
compared to the average total direct costs 
incurred to cancer patients. 
 
RESULTS AND DISCUSSION 
 
The number of samples obtained was 73 
patients, consisting 62 female patients and 11 
male patients, who met the inclusion criteria 
among a total population of 2261 patients. 
Among them, there were 39 breast cancer 
patients, 8 nasopharyngeal cancer patients, 14 
NHL cancer patients, 7 ovarian cancer patients, 
and 5 cervical cancer patients. A total of 66 
patients had no comorbidities disease. Mostly 
used treatment in cancer patients was 
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chemotherapy (57,53%), followed by a 
combination of chemotherapy and surgery 
(Table I). The group widely used for 
chemotherapy was combination of alkylating 
agent, anticancer antibiotics, and 
antimetabolite. The most common type of 
cancer treatment side effect was nausea-
vomiting (58,90%), and followed by 
combination of nausea-vomiting, anemia, and 
pain suffering (Table II). The percentage of side 
effects treatments cost compared to the total 
direct costs grouped based on type of cancer 
showed that cervical cancer had the highest 
percentage (8,87%) (Table III).  
Then the percentage of side effects 
treatments cost compared to the total direct 
costs of each type of therapy showed that 
radiation therapy had the highest percentage 
(12,09%) (Table IV). Mostly used therapy was 
vitamin B complex followed by histamine-2 
inhibitor (Table V). 
 
Table I. Distribution of the number of cancer patients based on treatment patterns in RSMS 
 Cancer type Total Percentage 
(%) Breast Nasopharinx NHL Ovarian Cervical 
Chemotherapy 32 - 10 -  42 57.53% 
Radiation 1 - - - 1 2 2.74% 
Chemotherapy and 
surgery 
6 2 4 7 - 19 26.03% 
Chemotherapy and 
radiation 
- - - - 2 2 2.74% 
Chemotherapy, 
radiation, and 
surgery 
- 6 - - 2 8 10.96% 
Total 73 100% 
 
Table II. Distribution of the cases of cancer therapy side effects in RSMS 
Types of side effects 
of therapy 
Number of patients 
Percentage 
(%) 
Breast Nasopharinx NHL Ovarian Cervical Total  
Nausea-vomiting 29 1     1 1 1 42 58.90 
Nausea-vomiting+bleeding 3 - - - - 3 4.11 
Nausea-vomiting + anemia 4 2 3 1 1 11 15.07 
Anemia+bleeding+nausea-
vomiting 
1 - - - - 1 1.37 
Nausea-
vomiting+anemia+pain 
2 4 - 5 1 12 16.44 
Anemia +pain+bleeding - - - - 1 1 1.37 
pain+bleeding+nausea-
vomiting+anemia 
- - - - 1 1 1.37 
Anemia+bleeding+pain+ 
nausea-vomiting+neutropenia 
- 1 - - - 1 1.37 
Total 73 100% 
 
Table III. The percentage of side effects treatments cost compared to the total direct costs for 
five top cancer patients in RSMS 
Type of 
cancer 
Average of direct cost 
(IDR) 
Average of side 
effect therapy cost 
(IDR) 
Side effect 
therapy cost 
compared to 
average of direct 
cost (%) 
Breast 19,633,621 1,715,373 8.73% 
Nasopharinx 16,455,038 1,149,049 6.98% 
NHL 18,283,619             360,778 1.97% 
Ovarian 25,224,706             911,118 3.61% 
Cervical 15,970,903 1,416,027 8.87% 
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Table IV. The percentage of side effects treatments cost compared to the total direct costs grouped 
by cancer treatment types in RSMS 
Type of cancer 
Average of 
direct cost 
(IDR) 
Average of 
side effect 
therapy cost 
(IDR) 
Side effect therapy cost 
compared to average of direct 
cost (%) 
Chemotherapy 18,849,096 1,425,718 7.56  
Radiation 12,815,304 1,548,808 12.09 
Chemotherapy and 
surgery 
21,563,158 1,011,593 4.69 
Chemotherapy and 
radiotherapy 
11,713,436 651,404 5.56 
Chemoptherapy, 
radiation, and surgery 
19,916,268 1,387,201 6.97 
 
Table V. Drug characteristics and cost used in cancer therapy side effects treatments in RSMS 
Group of therapy 
Number of patients 
Total cost 
 (in IDR) 
Breast Nasopharinx NHL Ovarian Cervical Total  
 
a. Serotonin antagonist 
-Ondansetron 
-Troposetron 
 
 
28 
- 
 
 
5 
4 
 
 
4 
- 
 
 
5 
2 
 
 
2 
1 
 
 
42 
7 
 
 
1,767,960 
1,203,125 
b. Dopamine antagonist 
- Metoclopramid 
- Domperidone 
 
8 
- 
 
8 
1 
 
13 
1 
 
7 
- 
 
4 
- 
 
40 
2 
 
3,089,020 
20,095 
c. Antacid - 3 13 3 1 20 64,984 
d. Histamine antagonist 
  - Ranitidin 
  - Cimetidine 
 
30 
- 
 
6 
- 
 
14 
- 
 
5 
1 
 
5 
1 
 
60 
2 
 
1,732,406 
15,400 
e. Corticosteroid 
  -Dexamethasone 
  -Methylprednisolone 
  -Kalmethasone 
 
8 
1 
1 
 
3 
6 
- 
 
3 
3 
- 
 
1 
3 
2 
 
2 
1 
- 
 
17 
14 
3 
 
140,789 
1,261,192 
61,256 
f. Vitamin b complex 39 5 13 6 5 68 97,794 
g. Blood transfusion 9 7 4 6 4 30 23,550,000 
h. Ferrous sulfate 2 4 0 5 5 16 17,195 
i. Vitamin K 0 2 1 4 0 7 24,788 
j. Tranexamic acid - 4 3 3 5 15 954,844 
k. Carbazochrome - 3 - 1 2 6 1,250,708 
l. Analgesic 
-Mefenamic acid 
-Ibuprofen 
-Ketorolac 
-Tramadol 
-Kalium 
diclofenac 
-Methampyrone 
-Natrium diclofenac 
-Piroxicam 
-Meloxicam 
-Ketoprofen 
-Paracetamol 
-Meperidine 
 
8 
1 
2 
- 
- 
     
     - 
- 
- 
- 
- 
- 
- 
 
5 
2 
2 
3 
3 
 
2 
2 
1 
- 
1 
4 
- 
 
6 
2 
2 
1 
- 
 
- 
- 
- 
- 
- 
4 
- 
 
7 
2 
6 
- 
- 
 
- 
- 
- 
- 
1 
- 
1 
 
- 
- 
1 
- 
- 
 
- 
- 
- 
1 
1 
2 
- 
 
26 
7 
13 
4 
3 
 
1 
2 
1 
1 
3 
10 
1 
 
56,868 
112,406 
564,859 
134,736 
   26,550 
 
      11,638 
       6,700 
       3,188 
     18,723 
    63,869 
    19,003 
    14,990 
*G- CSF : Granulocyte colony stimulating factor 
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This study showed there were 66 cancer 
patients with no comorbidities disease diagnose 
and 7 patients with cancer and comorbidities 
disease. Comorbidities disease suffered by all 
patients included was anemia. Medical reports 
report anemia as the side effects of cancer 
therapy.  
Results showed that cancer patients were 
given various therapies depending on the type 
and severity of cancer. It was observed that the 
most widely used treatment in cancer therapy 
was chemotherapy. In cancer patients, 
chemotherapy is used as adjuvant or 
neoadjuvant therapy. Another modes of 
treatment used in cancer therapy is shown in 
Table I. The various types of therapies caused 
various types of side effects. The results 
showed that nausea and vomiting are the most 
common cancer treatments side effects (59.80 
%), followed by combination of nausea 
vomiting, anemia, and pain suffering (16.44 %), 
and combination of nausea vomiting and 
anemia (15.11 %). In breast cancer and non 
Hodgkins lhympoma (NHL) patients, nausea 
and vomiting were induced by ≤ 1500 mg/m
2
 
cyclophosphamide and ≥ 60 mg/m
2
 doxorubicin 
possessing moderate to high emetogenic 
potential, and fluorouracil with the dose of 
1000 mg/m
2
 possessing low to moderate 
emetogenic potential. Nasopharinx and ovarian 
cancer patients also experienced nausea induced 
by 10 mg cisplatin (Jordan et al., 2005). 
Anemia may directly resulted from agents that 
induced the suppression of bone marrow to 
produce blood cells (myelosuppression), such 
as cyclophosphamide, or agents causing 
progressive dysfunction of renal tubules which 
ultimately leads to decreased renal production 
of endogenous erythropoietin and subsequently 
reduce production of red blood cells such as 
cisplatin (Rodgers, 2008; Emadi et al., 2009). 
Pain suffered may resulted from the use of 
regimens such as cisplatin that cause peripheral 
neuropathy, or due to physical sensory from 
surgical treatment and radiotherapy (British 
Pain Society, 2010).  
The percentage of cancer therapy side 
effects cost compared to the total direct costs 
grouped by type of cancer showed that cervical 
cancer had the highest percentage (8.87 %). 
Most cervical cancer patients got surgical and 
radiation therapy, causing anemia and bleeding 
as the side effects. Blood transfusion was 
required to manage them. Blood transfusion 
spent largest cost compared to other therapies 
like iron supplement or vitamins. It explains 
why cervical cancer therapy incurring highest 
cost therapy. The cost percentage in cervical 
cancer therapy side effects treatments is 
followed by breast cancer (8.73%). The cost 
percentage to overcome adverse events in 
breast cancer therapy was the second largest 
since many patients used serotonin inhibitor in 
nausea-vomiting therapy and blood transfusion 
in anemia therapy. Serotonin inhibitor was the 
most expensive therapy compared to other 
antiemetics used in this study, such as 
metochlopramide and histamine 2 antagonists. 
Besides, blood transfusion was also the most 
expensive compared other anemia therapies.  
Blood transfusion spent $568 to manage anemia 
because chemotherapy (Weiner et al., 2007).  
The cost percentage of side effect 
treatments compared to the total direct costs 
grouped based on modes of therapy showed that 
radiation had the highest percentage (12,09 %). 
In this study, 2 patients were given this therapy 
and all of them experienced anemia and 
bleeding. Thus, they spent a large cost due to 
blood transfusion, yielding a high average cost 
percentage compared to the others. Although 
the average cost of side effects treatments in the 
combination of chemotherapy-surgery was 
larger than the side effects treatments cost of 
combined chemotherapy-radiation, the average 
total direct costs incurring was higher (Rp 
21,563,158). Hence, it resulted in a small cost 
percentage.  
Some drugs are used either alone or in 
combination in side effects treatments. 
Research showed that for the treatment of 
nausea vomiting, mostly used antiemetic was 
histamin antagonis, but the drugs giving highest 
total cost was dopamine inhibitor, because 
many patients were given therapy with brand-
name-drugs instead of the generics. Total cost 
for the treatment of nausea and vomiting was 
Rp 8,033,779. The anemia therapies used in the 
study were vitamin B complex, blood 
transfusion, and iron and folic acid 
supplementation. Blood transfusion brings the 
largest costs that incurred to the patients. 
Bleeding was treated by using tranexamid acid, 
vitamin K, and carbazochrome with adona. The 
drug incurring the largest cost was adona used 
in post surgery or radiation. Total cost for the 
treatment of anemia and bleeding was Rp 
25,895,509. 
      The next therapy was pain suffering 
(analgesics) therapy, which use non-steroidal 
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anti-inflammatory class of analgesics and 
opioids. The drug incurring the largest cost was 
ketorolac. Total cost for analgesics therapy was 
Rp 1,033,530. In one case, the patient 
developed neutropenia and was treated with 
Granulocyte Colony Stimulating Factor (G-
CSF). Neutropenia therapy using G-CSF 
brought the most expensive unit price compared 
to the other therapies, even higher than the 
blood transfusion unit price. Total cost for the 
neutropenia therapy is Rp 1,168,750. 
Total cost for the treatment of side 
effects was Rp 36,131,568. Total cases of side 
effects which the patients suffered, either alone 
or in combination with the other adverse events, 
were 121 cases. The average cost for the 
handling of each case was Rp 298,604. In the 
cancer inpatient financing, government health 
insurance paid Rp 2.4 million per cancer patient 
hospitalization. It already covered all costs, 
including treatment, examination, fees, etc. But 
patient must be spent Rp 298,604, on side 
effects treatments, which made the portion of 
the cost for cancer therapy and other costs 
reduced. However, if the need for cancer 
therapy is abundant, then the hospital has to 
cover the lack of the cost, and it would be a 
burden for the hospital. Hospitals should give 
more attention to the handling of side effects in 
patients receiving cancer therapy, especially at 
nadir point. Nadir is a condition when patients 
suffered the worst condition of side effects. 
Based on the experiences, usually patients do 
not feel strong enough to undergo further 
treatment cycles resulting in the drop out of 
therapy. Cancer therapy may also highly 
consider dose selection, by considering the 
selection of the maximum therapeutic dose that 
the side effects can still be tolerated by the 
patients. 
This study had several limitations. First, 
the results of study just described retrospective 
data, then it couldn’t see the side effects therapy 
profile, meaning that the severity the difference 
of outcomes representing effectiveness of each 
drugs to manage cancer treatments side effects 
did not evaluated. However, this study showed 
how costly cancer treatments side effect that 
should be paid by cancer patients. It can be 
economic burden to them, and side effects 
decrease patient’s clinical condition and quality 
of life. If patients stopped their chemotherapy 
cycles because of the side effects, it would 
bring bad impacts to their health and cause a 
waste of all costly payment spent in previous 
treatments. Thus, this study could be a 
reference to hospital for managing the side 
effects of cancer treatments. We recommended 
a prospective design study to evaluate the cost 
effectiveness and clinical outcome of cancer 
treatments side effects therapy for further 
research to gather more information and 
detailed data. 
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